Fukuda Haruhisa, Ikeda Shunya, Shiroiwa Takeru, Fukuda Takashi
Department of Health Care Administration and Management, Kyushu University Graduate School of Medical Sciences, 3-1-1, Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan.
School of Pharmacy, International University of Health and Welfare, 2600-1, Kitakanemaru, Ōtawara, Tochigi, 324-8501, Japan.
Pharmacoeconomics. 2016 Oct;34(10):1005-14. doi: 10.1007/s40273-016-0402-3.
Inaccurate estimates of diabetes-related healthcare costs can undermine the efficiency of resource allocation for diabetes care. The quantification of these costs using claims data may be affected by the method for defining diagnoses.
The aims were to use panel data analysis to estimate diabetes-related healthcare costs and to comparatively evaluate the effects of diagnostic definitions on cost estimates.
Monthly panel data analysis of Japanese claims data.
The study included a maximum of 141,673 patients with type 2 diabetes who received treatment between 2005 and 2013.
Additional healthcare costs associated with diabetes and diabetes-related complications were estimated for various diagnostic definition methods using fixed-effects panel data regression models.
The average follow-up period per patient ranged from 49.4 to 52.3 months. The number of patients identified as having type 2 diabetes varied widely among the diagnostic definition methods, ranging from 14,743 patients to 141,673 patients. The fixed-effects models showed that the additional costs per patient per month associated with diabetes ranged from US$180 [95 % confidence interval (CI) 178-181] to US$223 (95 % CI 221-224). When the diagnostic definition excluded rule-out diagnoses, the diabetes-related complications associated with higher additional healthcare costs were ischemic heart disease with surgery (US$13,595; 95 % CI 13,568-13,622), neuropathy/extremity disease with surgery (US$4594; 95 % CI 3979-5208), and diabetic nephropathy with dialysis (US$3689; 95 % CI 3667-3711).
Diabetes-related healthcare costs are sensitive to diagnostic definition methods. Determining appropriate diagnostic definitions can further advance healthcare cost research for diabetes and its applications in healthcare policies.
对糖尿病相关医疗费用的不准确估计可能会损害糖尿病护理资源分配的效率。使用索赔数据对这些费用进行量化可能会受到诊断定义方法的影响。
旨在使用面板数据分析来估计糖尿病相关医疗费用,并比较评估诊断定义对费用估计的影响。
对日本索赔数据进行月度面板数据分析。
该研究纳入了2005年至2013年间接受治疗的最多141,673例2型糖尿病患者。
使用固定效应面板数据回归模型,针对各种诊断定义方法估计与糖尿病及糖尿病相关并发症相关的额外医疗费用。
每位患者的平均随访期为49.4至52.3个月。在不同的诊断定义方法中,被确定为患有2型糖尿病的患者数量差异很大,从14,743例到141,673例不等。固定效应模型显示,每位患者每月与糖尿病相关的额外费用从180美元[95%置信区间(CI)178 - 181]到223美元(95% CI 221 - 224)不等。当诊断定义排除排除性诊断时,与较高额外医疗费用相关的糖尿病相关并发症为手术治疗的缺血性心脏病(13,595美元;95% CI 13,568 - 13,622)、手术治疗的神经病变/肢体疾病(4594美元;95% CI 3979 - 5208)以及透析治疗的糖尿病肾病(3689美元;95% CI 3667 - 3711)。
糖尿病相关医疗费用对诊断定义方法敏感。确定合适的诊断定义可以进一步推动糖尿病医疗费用研究及其在医疗政策中的应用。